https://www.lytixbiopharma.com/_next/static/chunks/76107467477bc496.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7

1(globalThis.TURBOPACK||(globalThis.TURBOPACK=[])).push(["object"==typeof document?document.currentScript:void 0,279434,e=>{"use strict";var t=e.i(843476),a=e.i(657688),i=e.i(522016),n=e.i(271645),r=e.i(778917);let o=(e,t,a,i)=>({date:e,title:t,body:i,contentPath:a.startsWith("http")?void 0:a}),s=[o("Aug 20, 2024","Intervju med Øystein Rekdal i Finansavisen Børsmorgen:","/news/487/130/Intervju-med-%C3%98ystein-Rekdal-i-Finansavisen-B%C3%B8rsmorgen.html",`\xd8ystein Rekdal ble nylig intervjuet i B\xf8rsmorgen p\xe5 Finansavisen TV, hvor han diskuterte de imponerende resultatene presentert av Verrica Pharmaceuticals.
2
3Intervjuet finner du [her](https://tv.finansavisen.no/m/nC9CMU8w/toppsjefen-i-lytix-biopharma-en-milepl-for-selskapet?r=TPqO7NJI).`),o("Aug 16, 2024","View Lytix Biopharma's presentation of Phase II clinical results in Basal Cell Carcinoma","/news/486/130/View-Lytix-Biopharmas-presentation-of-Phase-II-clinical-results-in-Basal-Cell-Carcinoma.html",`The English version of the presentation can be viewed [here](https://hm-videoproduksjon.filemail.com/d/hudzwtjurensjvu).
4
5The Norwegian version can of the presentation can be viewed [here](https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240815_12).
6
7Both presentations are also available under Investors > Reports and Presentations > Presentations, or follow this [link](/investors/reports-and-presentations/presentations).`),o("Apr 22, 2024","CEO Presentation and Q&A with Redeye AB","/news/485/130/CEO-Presentation-and-QA-with-Redeye-AB.html",`Our CEO, \xd8ystein Rekdal, gives an update on upcoming milestones including the Verrica Phase II readout expected in Q2 and the ongoing capital raise. The presentation can be found [here](https://redeye-3.wistia.com/medias/e5mwff3sx0).`),o("Nov 27, 2023","Øystein Rekdal, CEO in Lytix Biopharma, presented at Redeye Life Science Day 2023 in Stockholm – 23rd of November","/news/484/130/%C3%98ystein-Rekdal-CEO-in-Lytix-Biopharma-presented-at-Redeye-Life-Science-Day-2023-in-Stockholm-23rd-of-November.html","[Here](https://www.redeye.se/video/event-presentation/963528/lytix-biopharma-ceo-oystein-rekdal-presents-at-redeye-life-science-day-2023-23-november?utm_source=video&utm_medium=email) is a recording of the short pitch presentation and the following Q&A session with Redeye's research analyst Richard Ramanius."),o("Aug 18, 2023","Redeye interviewed Øystein Rekdal about Lytix and his role as CEO","/news/483/130/Redeye-interviewed-%C3%98ystein-Rekdal-about-Lytix-and-his-role-as-CEO.html","[Listen to the interview.](https://www.redeye.se/research/933269/lytix-biopharma-get-to-know-ceo-oystein-rekdal)"),o("Aug 14, 2023","The positive interim Phase II data with LTX-315 from Verrica Pharmaceuticals Inc. (Lytix Biopharma's licensing partner) stirs attention","/news/482/130/The-positive-interim-Phase-II-data-with-LTX-315-from-Verrica-Pharmaceuticals-Inc.-Lytix-Biopharmas-licensing-partner-stirs-attention.html",`Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc (“Verrica”) reported lesion clearance data from Part 1 of an ongoing Phase II study of VP-315 (formerly known as LTX-315) for the treatment of basal cell carcinoma (BCC). Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology indications and is currently performing a clinical Phase II study in patients with BCC.
8
9The results were orally presented at the 2023 American Academy of Dermatology Innovation Academy meeting, August 10-13, in Tampa, Florida, and the data stirs attention.
10
11Among the articles, check:
12- [Scrip](https://scrip.pharmaintelligence.informa.com/SC148868/Verricas-Anticancer-Efforts-Kick-Off-With-Promising-Early-Phase-II-BCC-Data)
13- [MedWatch](https://medwatch.no/nyheter/legemidler_biotek/article16346376.ece) (behind paywall)
14- [Nordlys.no](https://www.nord24.no/usa-studie-foran-skjema-styrket-tro-pa-gevinst-etter-lovende-funn/s/5-32-187033) (in Norwegian and behind paywall)
15- [FA.no](https://www.finansavisen.no/helse/2023/08/11/8028243/revolusjonerende-kreftstudie-sender-aksje-til-vaers?internal_source=sistenytt) (in Norweg

15ian)
16- [TV2.no](https://www.tv2.no/nyheter/utenriks/norsk-forsker-med-sensasjonelt-kreft-gjennombrudd/15958877/) (in Norwegian)`),o("Aug 10, 2023","Redeye initiates coverage of Lytix Biopharma","/news/481/130/Redeye-initiates-coverage-of-Lytix-Biopharma.html","Find the Research Report [here](https://www.redeye.se/research/929033/lytix-biopharma-new-immunotherapy-with-unique-mode-of-action?utm_medium=email&notificationId=e3979862-c7ba-4aa3-823c-e432d301384f)"),o("May 30, 2023","Lytix Biopharma's innovative and unique solution emphasized in national clinical research report","/news/480/130/Lytix-Biopharmas-innovative-and-unique-solution-emphasized-in-national-clinical-research-report.html",`On Friday 26 May, the Minister of Health and Care in Norway, Ingvild Kjerkol, received a report from the regional health undertakings with national key figures and a mention of the best research and innovation projects in the Norwegian hospitals in 2022.
17
18This is the tenth report of its kind, and Lytix Biopharma’s Phase I international multicenter study with LTX-315 (“Safety, antitumor efficacy and T-cell response in a dose-escalating study of oncolytic peptide LTX-315 in patients with solid tumors") was among the mentioned projects.
19
20Read about the study [here](https://kommunikasjon.ntb.no/pressemelding/injisering-direkte-i-kreftsvulst-er-testet-pa-mennesker?publisherId=17847310&releaseId=17969557&lang=no)`),o("May 12, 2023","Hear our CEO, Øystein Rekdal, explaining how our technology has the potential to solve the major challenge in current cancer therapy","/news/479/130/Hear-our-CEO-%C3%98ystein-Rekdal-explaining-how-our-technology-has-the-potential-to-solve-the-major-challenge-in-current-cancer-therapy.html",`Hear our CEO, \xd8ystein Rekdal, explaining how our technology has the potential to solve the major challenge in current cancer therapy and can work in a number of cancer types.
21
22[Link to today’s live interview at FaTV (Finansavisen)](https://tv.finansavisen.no/m/obwryzn7/lytix-lper-om-kapp-med-big-pharma?list=e9khv1kq)`),o("May 8, 2023",'"Norwegian cancer medicine is attracting attention", read article in TV2 news',"/news/478/130/Norwegian-cancer-medicine-is-attracting-attention-read-article-in-TV2-news.html",`Lytix Biopharma's molecule destroys cancer cells and turns them into a vaccine.
23
24Lytix and Dr. James Allison featured in TV2 news after CEO \xd8ystein Rekdal was invited by New York Academy of Sciences to give a presentation at ‘Frontiers in Cancer Immunotherapy 2023’.
25
26[Read the article here](https://www.tv2.no/nyheter/utenriks/hundretusenvis-av-liv-kan-bli-reddet/15718730/)`),o("Apr 12, 2023","First patient dosed in Part 2 of Verrica Pharmaceuticals' Phase II study evaluating LTX-315","/news/477/130/First-patient-dosed-in-Part-2-of-Verrica-Pharmaceuticals-Phase-II-study-evaluating-LTX-315.html",`Our licensing partner Verrica Pharmaceuticals today announced that the first patient has been dosed in Part 2 of their Phase II study evaluating our lead compound, LTX-315 - by Verrica designated as VP-315 - for treatment of basal cell carcinoma.
27
28The progress into Part 2 is based on the positive results from the recently completed Part 1 of the study, where LTX-315 showed clinical evidence of activity in patients who received a higher dose range.
29
30The CEO of Verrica, Ted White, made this comment: “As a novel oncolytic peptide administered directly at the tumor site, VP-315 has the potential to offer a non-surgical alternative for the approximately 3.6 million cases of basal cell carcinoma diagnosed in the U.S. each year.”
31
32For the entire press release from Verrica, click [here](https://www.globenewswire.com/news-release/2023/04/12/2645192/0/en/Verrica-Pharmaceuticals-Announces-Dosing-of-the-First-Patient-in-Part-2-of-Phase-2-Study-Evaluating-VP-315-for-the-Treatment-of-Basal-Cell-Carcinoma.html).
33
34And for article at MedWatch, click [here](https://medwatch.no/nyheter/legemidler_biotek/article15580122.ece?utm_campaign=MedWatch&utm_content=2023-04-13&utm_medium=email&utm_source=medwatch_no).`),o("Mar 22, 2023","Lytix Biopharma appoints Karsten Bruins Slot as Director Clinical Development","/news/476/130/Lytix-Biopharma-appoints-Karsten-Bruins-Slot-as-Director-Clinical-Development.html",`Lytix Biopharma today announces the appointment of Karsten Bruins Slot as Director Clinical Development, providing scientific and clinical guidance to cross-functional teams and colleagues.
35
36Most recently Karsten Bruins Slot served as ‘Medical Director – Head of Oncology’ in Nykode Therapeutics.
37
38Karsten Bruins Slot has his MD from University of Groningen, The Netherlands, and received his doctorate at Oslo University Hospital in 2009. The same year he joined The Norwegian Medicines Agency, where he was Norway's representative in the CHMP - EU's scientific expert panel for the approval of medicinal products. In May 2017, he moved to the pharmaceutical industry and started at Roche as Country Medical Manager. Two years later he was promoted to Medical Director and stayed in that position until he joined Nykode in August 2021.
39
40“We are very happy to welcome Karsten to our team”, says \xd8ystein Rekdal, CEO of Lytix. “Karsten brings with him valuable experience from clinical work both in biotech and big pharma as well as regulatory experience”.
41
42Karsten Bruins Slot enters his position at Lytix today, March 22nd, 2023, and his focus ahead will be the ongoing ATLAS-IT-05 study and the preparations for the Phase I study ATLAS-IT-06 with LTX-401, Lytix’ second molecule to enter the clinic.
43
44“To participate in the development of new types of immunotherapies for cancer patients is at my heart. At Lytix I find an opportunity to be at the forefront of immuno-oncology and contribute to bringing new treatment options to cancer patients,” says Karsten Bruins Slot.
45
46[Karsten Bruins Slot (LinkedIn)](https://www.linkedin.com/in/karsten-bruins-slot-488a817/)`),o("Mar 14, 2023","Lytix is hiring - looking for a CMC Manager","/news/475/130/Lytix-is-hiring-looking-for-a-CMC-Manager.html",`Main Re

46sponsibilities include, but are not limited to:
47* Formulation and development activities, manufacture, quality control and release of Drug Substance and Drug Product for use in pre-clinical and clinical studies
48* Issuing development reports, CMC documentation etc.
49* Selection, qualification and follow-ups of CRO’s, CDMO’s and Consultants as appropriate
50* Preparation of regulatory documentation for clinical trial applications
51* Development and manufacture that are conducted in accordance with regulatory requirements (EMA/FDA, GMP, ISO, lCH etc) and clinical trial applications (IMPD, IND)
52
53[For more information](https://www.borka.no/jobb/lytix-biopharma-is-hiring-a-cmc-manager/)`),o("Mar 9, 2023","Our CEO, Øystein Rekdal, has been interview by Health Talk","/news/474/130/Our-CEO-%C3%98ystein-Rekdal-has-been-interview-by-Health-Talk.html",`Fremskritt i egne kliniske studier og for lisensieringspartner Verrica Pharmaceuticals med LTX-315. Ny legemiddelkandidat er snart klar for kliniske studier. \xd8ystein Rekdal har gode og travle dager p\xe5 jobb som direkt\xf8r i det norske biotekselskapet Lytix Biopharma.
54
55[Read the article](https://www.healthtalk.no/ltx-315-lytix-biopharma-onkolytisk-virus/lytix-biopharma-sjefen-ser-lyse-tider-for-selskapets-utprovende-kreftmedisiner/169567) (only in Norwegian)`),o("Mar 7, 2023","Verrica Pharmaceuticals with positive update on how they are advancing our lead compound LTX-315 through their Phase II trial","/news/473/130/Verrica-Pharmaceuticals-with-positive-update-on-how-they-are-advancing-our-lead-compound-LTX-315-through-their-Phase-II-trial.html",`An update was given yesterday by Ted White, the CEO of our partner Verrica Pharmaceuticals, on how they are advancing our lead compound LTX-315 through their Phase II trial. Satisfied and encouraged by the efficacy they observed in part 1 of the study in basal cell carcinoma patients, they now plan to enroll the first patient in part 2 in April. In Part 2 Verrica will explore dosing frequency and treatment regimens and be looking for clinical necrosis and abscopal effects.
56
57For more information:
58
59* listen to Ted White’s presentation from yesterday, at TD Cowen Health Care Conference (after 14 minutes): [https://wsw.com/webcast/cowen132/vrca/200776](https://wsw.com/webcast/cowen132/vrca/200776)
60
61* and/or see Verrica’s press release: [https://verrica.com/press_release/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results](https://verrica.com/press_release/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results)`),o("Nov 23, 2022","Lytix Biopharma held a CMD November 22nd, 2022 - webcast replay is available","/news/472/130/Lytix-Biopharma-held-a-CMD-November-22nd-2022-webcast-replay-is-available.html",`Lytix Biopharma held a Capital Markets Day primarily focusing on the core and versatility of the Lytix Technology Platform and selected parts of our clinical development program. The CMD was a live event (open for physical attendance at Hotel Continental in Oslo, Norway) and a live webcast.
62
63The program included presentations and Q&A with
64
65\xd8ystein Rekdal, CEO of Lytix
66- What makes Lytix' immuno-oncology technology platform stand out as unique?
67
68Niels Junker, Chief Physician at Herlev Hospital and investigator at the ATLAS-IT-04 proof-of-concept study
69- Investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma – a pilot study.
70
71Aur\xe9lien Marabelle, Professor of Clinical Immunology, Universit\xe9 Paris Saclay and an internationally recognized expert on intratumoral cancer treatment
72- Liver cancer: Current treatment modalities and how oncolytic molecules could play an integral role in future liver cancer treatment.
73
74Stephen Worsley, CBO of Lytix
75- The commercial versatility of oncolytic molecules: What can LTX-315/401 bring to the immuno-oncology table/offer to the pharmaceutical industry.
76
77The webcast replay is available [here](https://events.webcast.no/lytix-biopharma/a7s3okRUQLwkPgZ728vi/6o493Nq74a6yYAYHgqMd)
78
79For further information, please contact Ole Peter Nordby, Head of IR & Communication Manager ([email protected])`),o("Jun 20, 2022","Lytix Biopharma to present at the 5th Annual Next-Gen Immuno-Oncology Conference in Boston, USA","/news/471/130/Lytix-Biopharma-to-present-at-the-5th-Annual-Next-Gen-Immuno-Oncology-Conference-in-Boston-USA.html",`The conference will address the challenges and future directions in Immuno-Oncology research, and on day 2 of the conference, June 24th, Lytix will present how to address Tumor Heterogeneity with non-viral Oncolytic agents - an unsolved issue in Cancer Immunotherapy.
80
81Oncolytic molecules have shown ability to kill drug resistant and drug sensitive cancer cells and evoke the innate immune system, and clinical results demonstrate promising potential for combining Lytix’ oncolytic molecules with immune checkpoint inhibitors or adoptive T-cell therapies.
82
83[See conference website](https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-next-gen-immuno-oncology-conference/#overviews) for more info.`),o("Jun 5, 2022","Lytix Biopharma with new data at ASCO - featured in Finansavisen and in Dagens Medisin","/news/470/130/Lytix-Biopharma-with-new-data-at-ASCO-featured-in-Finansavisen-and-in-Dagens-Medisin.html",`Lytix announced data from its ATLAS-IT-04 trial in patients with metastatic soft tissue sarc

83oma (STS) as a poster at the American Society of Clinical Oncology (ASCO) 2022, June 5th. Data from this Phase II proof of concept study shows that LTX-315 in combination with ACT was able to stabilize the disease in 3 out of 4 fully treated patients in this hard-to-treat patient population, and that the LTX-315 treatment generated tumor-specific T cells.
84
85In connection with the presentation of the new data, Lytix was interviewed and featured in Dagens Medisin and Finansavisen.
86
87[Read the article in Dagens Medisin](https://www.dagensmedisin.no/artikler/2022/06/05/lytix-med-nye-sarkom-data-pa-asco--positivt/)
88
89[Read the article in Finansavisen](https://finansavisen.no/nyheter/helse/2022/06/05/7877784/opploftende-studie-fra-lytix-biopharma)`),o("Jun 2, 2022","See the recording of Lytix Biopharma's CMD (June 1st 2022)","/news/469/130/See-the-recording-of-Lytix-Biopharmas-CMD-June-1st-2022.html",`Lytix Biopharma hosted a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022.
90
91The event was open for physical attendance in Oslo, Norway, as well as a live webcast, and it lastet for two hours, including Q&A.
92
93Speakers was Ted White, CEO of Verrica Pharmaceuticals Inc. (“Verrica”), Gary Goldenberg, CMO of Verrica, Aurelien Marabelle, visiting professor at Stanford University and an internationally recognized expert on intratumoral cancer treatment, and \xd8ystein Rekdal, CEO of Lytix Biopharma.
94
95Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize its lead compound, LTX-315, for dermatologic oncology conditions, and the first patient has been dosed in Verrica’s Phase II study evaluating LTX-315 for intratumoral treatment of basal cell carcinoma (skin cancer). At the CMD the focus will be on the rationale and current state-of-the-art regarding intratumoral treatment of cancer patients. Most of all, the agreement between Verrica and Lytix and the commercial opportunity for and clinical value of LTX-315 in treatment of cell carcinomas will be highlighted.
96
97[See the recording](https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220601_1)`),o("May 3, 2022","Lytix Biopharma will host Capital Markets Day - June 1, 2022","/news/468/130/Lytix-Biopharma-will-host-Capital-Markets-Day-June-1-2022.html",`Lytix Biopharma (“Lytix”), is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022.
98
99The event will be open for physical attendance in Oslo, Norway, as well as a live webcast. It is scheduled to start at 14.00 CET, and is expected to last approximately two hours, including Q&A.
100
101Speakers will be Ted White, CEO of Verrica Pharmaceuticals Inc. (“Verrica”), Gary Goldenberg, CMO of Verrica, Aurelien Marabelle, visiting professor at Stanford University and an internationally recognized expert on intratumoral cancer treatment, and \xd8ystein Rekdal, CEO of Lytix Biopharma.
102
103Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize its lead compound, LTX-315, for dermatologic oncology conditions, and the first patient has been dosed in Verrica’s Phase II study evaluating LTX-315 for intratumoral treatment of basal cell carcinoma (skin cancer). At the CMD the focus will be on the rationale and current state-of-the-art regarding intratumoral treatment of cancer patients. Most of all, the agreement between Verrica and Lytix and the commercial opportunity for and clinical value of LTX-315 in treatment of cell carcinomas will be highlighted.
104
105Further details of the agenda and registration details will follow.`),o("Apr 7, 2022","Lytix Biopharma presents at DKBio 2022 today","/news/467/130/Lytix-Biopharma-presents-at-DKBio-2022-today.html"),o("Mar 1, 2022","Lytix Biopharma featured in Nordlys","/news/465/130/Lytix-Biopharma-featured-in-Nordlys.html"),o("Dec 17, 2021","Øystein Rekdal, CEO in Lytix Biopharma, interviewed live at 'Økonomi-nyheter', Finansavisen","/news/460/130/%C3%98ystein-Rekdal-CEO-in-Lytix-Biopharma-interviewed-live-at-%C3%98konomi-nyheter-Finansavisen.html"),o("Dec 8, 2021","Lytix Biopharma was today's guest at The Radium podcast","/news/459/130/Lytix-Biopharma-was-todays-guest-at-The-Radium-podcast.html"),o("Nov 22, 2021","Lytix Biopharma will release its third quarter 2021 results on Thursday, 25 November","/news/456/130/Lytix-Biopharma-will-release-its-third-quarter-2021-results-on-Thursday-25-November.html"),o("Nov 18, 2021","FDA has accepted Verrica's IND for LTX-315 in treatment of basal cell carcinoma","/news/455/130/FDA-has-accepted-Verricas-IND-for-LTX-315-in-treatment-of-basal-cell-carcinoma.html"),o("Nov 12, 2021","Lytix presents encouraging preclinical data in triple negative breast cancer in collaboration with Weill Cornell Medicine","/news/454/130/Lytix-presents-encouraging-preclinical-data-in-triple-negative-breast-cancer-in-collaboration-with-Weill-Cornell-Medicine.html"),o("Nov 2, 2021","On this day in 1982 Nobel Prize laureate, and our SAB member, James Allison published a paper in the Journal of Immunology identifying the protein structure of the T-cell receptor","/news/453/130/On-this-day-in-1982-Nobel-Prize-laureate-and-our-SAB-member-James-Allison-published-a-p

105aper-in-the-Journal-of-Immunology-identifying-the-protein-structure-of-the-T-cell-receptor-the-previously-mysterious-ignition-switch-for-immune-response.html"),o("Oct 22, 2021","Lytix Biopharma granted European Patent for LTX-315 in combination with chemotherapeutic agent","/news/452/130/Lytix-Biopharma-granted-European-Patent-for-LTX-315-in-combination-with-chemotherapeutic-agent.html"),o("Oct 18, 2021","Øystein Rekdal presents Lytix Biopharma at Finansavisen's 'INVESTORDAGENE 2021'","/news/451/130/%C3%98ystein-Rekdal-presents-Lytix-Biopharma-at-Finansavisens-INVESTORDAGENE-2021.html"),o("Sep 23, 2021","Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US","/news/450/130/Lytix-Biopharma-strengthens-patent-protection-of-lead-candidate-LTX-315-in-the-US.html"),o("Aug 27, 2021","Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market","/news/449/130/Lytix-Biopharma-second-quarter-and-first-half-of-2021-results-Fueled-to-target-the-US-cancer-market.html"),o("Aug 23, 2021","Lytix Biopharma presents first half and second quarter 2021 results, Friday 27 August","/news/448/130/Lytix-Biopharma-presents-first-half-and-second-quarter-2021-results-Friday-27-August.html"),o("Jul 15, 2021","Lytix Biopharma initiates the Phase II combination study in the US with LTX-315 and Pembrolizumab in patients with solid tumors","/news/447/130/Lytix-Biopharma-initiates-the-Phase-II-combination-study-in-the-US-with-LTX-315-and-Pembrolizumab-in-patients-with-solid-tumors.html"),o("Jun 14, 2021","Lytix Biopharma ASA: Publication of Information Document","/news/446/130/Lytix-Biopharma-ASA-Publication-of-Information-Document.html"),o("May 31, 2021","Lytix Biopharma ASA: Contemplated private placement and listing on Euronext Growth Oslo","/news/445/130/Lytix-Biopharma-ASA-Contemplated-private-placement-and-listing-on-Euronext-Growth-Oslo.html"),o("May 25, 2021","Lytix Biopharma strengthens the board of directors with nominating Marie-Louise Fjällskog, Evelina Vågesjö and Jayson Rieger as new directors","/news/444/130/Lytix-Biopharma-strengthens-the-board-of-directors-with-nominating-Marie-Louise-Fj%C3%A4llskog-Evelina-V%C3%A5gesj%C3%B6-Kjetil-Hestdal-and-Jayson-Rieger-as-new-directors.html"),o("May 10, 2021","Lytix Biopharma announces positive Phase I data for LTX-315","/news/443/130/Lytix-Biopharma-announces-positive-Phase-I-data-for-LTX-315.html"),o("Apr 13, 2021","Lytix Biopharma decides to initiate a process of raising capital","/news/442/130/Lytix-Biopharma-decides-to-initiate-a-process-of-raising-capital.html"),o("Mar 29, 2021","Lytix Biopharma enters into an exclusive license agreement with the Arctic University of Norway for a class of new drug candidates - and forms a strategic partnership with the US-based Aurelius Biotherapeutics","/news/441/130/Lytix-Biopharma-enters-into-an-exclusive-license-agreement-with-the-Arctic-University-of-Norway-for-a-class-of-new-drug-candidates-and-forms-a-strategic-partnership-with-the-US-based-Aurelius-Biotherapeutics.html"),o("Mar 1, 2021","Lytix Biopharma has appointed Gry Stensrud as Chief Technology Officer","/news/440/130/Lytix-Biopharma-has-appointed-Gry-Stensrud-as-Chief-Technology-Officer.html"),o("Feb 27, 2021","CEO in Lytix Biopharma gives oral presentation at ESMO targeted anticancer therapies virtual congress 2021","/news/439/130/CEO-in-Lytix-Biopharma-gives-oral-presentation-at-ESMO-targeted-anticancer-therapies-virtual-congress-2021.html"),o("Feb 26, 2021",'Lytix Biopharma is delighted to share our latest publication in "Trends in Cancer"',"/news/438/130/Lytix-Biopharma-is-delighted-to-share-our-latest-publication-in-Trends-in-Cancer.html"),o("Jan 29, 2021","Radforsk invited Lytix Biopharma to their podcast – Radium","/news/437/130/Radforsk-invited-Lytix-Biopharma-to-their-podcast-Radium.html"),o("Jan 20, 2021","Lytix Biopharma announces FDA clearance of IND for starting a Phase II study in the US","/news/436/130/Lytix-Biopharma-announces-FDA-clearance-of-IND-for-starting-a-Phase-II-study-in-the-US.html"),o("Oct 10, 2020","Lytix Biopharma is looking for a Head of CMC","/news/434/130/Lytix-Biopharma-is-looking-for-a-Head-of-CMC.html"),o("Oct 5, 2020","Lytix Biopharma has appointed Jørund Sollid as Chief Business Officer","/news/435/130/Lytix-Biopharma-has-appointed-J%C3%B8rund-Sollid-as-Chief-Business-Officer.html"),o("Sep 11, 2020","Lytix Biopharma contributed on manuscript published online at ascopubs","/news/433/130/Lytix-Biopharma-contributed-on-manuscript-published-online-at-ascopubs.html"),o("Aug 12, 2020","Lytix Biopharma enter

105s milestone agreement with Verrica Pharmaceuticals for its lead candidate LTX-315","/news/432/130/Lytix-Biopharma-enters-milestone-agreement-with-Verrica-Pharmaceuticals-for-its-lead-candidate-LTX-315.html"),o("May 25, 2020","CSO in Lytix Biopharma participates in panel debate arranged by OCC, LMI and NCS","/news/431/130/CSO-in-Lytix-Biopharma-participates-in-panel-debate-arranged-by-OCC-LMI-and-NCS.html"),o("Feb 10, 2020","Lytix Biopharma featured in both E24 and Bergensavisen","/news/430/130/Lytix-Biopharma-featured-in-both-E24-and-Bergensavisen.html"),o("Jan 15, 2020","Lytix Biopharma among 11 finalists at the third annual Lyfebulb-Helsinn Innovation Summit","/news/429/130/Lytix-Biopharma-among-11-finalists-at-the-third-annual-Lyfebulb-Helsinn-Innovation-Summit.html"),o("Dec 23, 2019","James P. Allison, SAB member in Lytix Biopharma, featured in VG today - and Lytix is mentioned","/news/428/130/James-P.-Allison-SAB-member-in-Lytix-Biopharma-featured-in-VG-today-and-Lytix-is-mentioned.html"),o("Dec 11, 2019","Today Lytix Biopharma's CEO gave his presentation 'Addressing heterogeneity: A hot topic' at ESMO","/news/427/130/Today-Lytix-Biopharmas-CEO-gave-his-presentation-Addressing-heterogeneity-A-hot-topic-at-ESMO.html"),o("Dec 4, 2019","Lytix Biopharma announces changes in the Board of Directors","/news/426/130/Lytix-Biopharma-announces-changes-in-the-Board-of-Directors.html"),o("Dec 2, 2019","Oral presentation by Lytix Biopharma at Esmo 2019","/news/425/130/Oral-presentation-by-Lytix-Biopharma-at-Esmo-2019.html"),o("Nov 11, 2019","Lytix Biopharma is featured in Finansavisen, talking about Iovance collaboration and funding","/news/424/130/Lytix-Biopharma-is-featured-in-Finansavisen-talking-about-Iovance-collaboration-and-funding.html"),o("Nov 10, 2019","Lytix Biopharma announces a clinical collaboration agreement with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)","/news/423/130/Lytix-Biopharma-announces-a-clinical-collaboration-agreement-with-Iovance-Biotherapeutics-Inc.-NASDAQ-IOVA.html"),o("Oct 23, 2019","New publication in collaboration with Mikael Pittet and his team at Massachusetts General Hospital and Harvard Medical School","/news/422/130/New-publication-in-collaboration-with-Mikael-Pittet-and-his-team-at-Massachusetts-General-Hospital-and-Harvard-Medical-School.html"),o("Sep 12, 2019","Lytix Biopharma ASA appoints Øystein Rekdal as the new CEO","/news/421/130/Lytix-Biopharma-ASA-appoints-%C3%98ystein-Rekdal-as-the-new-CEO.html"),o("Jun 20, 2019","Lytix Biopharma announces two recent publications on LTX-401, a second generation molecule developed for treatment of visceral tumors","/news/420/130/Lytix-Biopharma-announces-two-recent-publications-on-LTX-401-a-second-generation-molecule-developed-for-treatment-of-visceral-tumors.html"),o("Jun 20, 2019","Intratumoral treatment with LTX-315 causes regression of Desmoid Tumor - A case history","/news/419/130/Intratumoral-treatment-with-LTX-315-causes-regression-of-Desmoid-Tumor-A-case-history.html"),o("Jun 13, 2019","Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma joins Lytix as Company Strategic Advisors and in SAB","/news/418/130/Nobel-Laureate-Dr-James-Allison-and-Oncologist-Dr-Padmanee-Sharma-joins-Lytix-as-Company-Strategic-Advisors-and-in-SAB.html"),o("May 14, 2019","Lytix Biopharma is invited as a speaker at a Medicon Valley Alliance meeting","/news/417/130/Lytix-Biopharma-is-invited-as-a-speaker-at-a-Medicon-Valley-Alliance-meeting.html"),o("Mar 20, 2019","Lytix Biopharma will present 3 posters at AACR 2019","/news/416/130/Lytix-Biopharma-will-present-3-posters-at-AACR-2019.html"),o("Jan 15, 2019","Lytix Biopharma announces dosing of first patient in a Phase II study","/news/415/130/Lytix-Biopharma-announces-dosing-of-first-patient-in-a-Phase-II-study.html"),o("Nov 27, 2018","Lytix Biopharma presented at the Investival showcase at the Jefferies Healthcare Conference in London","/news/414/130/Lytix-Biopharma-presented-at-the-Investival-showcase-at-the-Jefferies-Healthcare-Conference-in-London.html"),o("Nov 21, 2018","Lytix Biopharma announces positive top-line data from a Phase 1 study with LTX-315","/news/413/130/Lytix-Biopharma-announces-positive-top-line-data-from-a-Phase-1-study-with-LTX-315.html"),o("Oct 24, 2018","Lytix Biopharma is covered in Norweg

105ian Airline's magazine","/news/412/130/Lytix-Biopharma-is-covered-in-Norwegian-Airlines-magazine.html"),o("Sep 27, 2018","Sarcoma study with LTX-315 open for recruitment","/news/411/130/Sarcoma-study-with-LTX-315-open-for-recruitment.html"),o("Aug 20, 2018","Lytix Biopharma appoints Gjest Breistein as the new CFO","/news/410/130/Lytix-Biopharma-appoints-Gjest-Breistein-as-the-new-CFO.html"),o("Jun 12, 2018","Lytix Biopharma strengthens management with appointment of Hamina Patel as CMO","/news/409/130/Lytix-Biopharma-strengthens-management-with-appointment-of-Hamina-Patel-as-CMO.html"),o("May 25, 2018","Lytix Biopharma will present preliminary data at ASCO from a phase I/II study","/news/408/130/Lytix-Biopharma-will-present-preliminary-data-at-ASCO-from-a-phase-III-study.html"),o("May 15, 2018","Lytix Biopharma announces changes in the board of directors","/news/407/130/Lytix-Biopharma-announces-changes-in-the-board-of-directors.html"),o("May 14, 2018","Lytix Biopharma announces Sudhir Agrawal to join as scientific advisor","/news/406/130/Lytix-Biopharma-announces-Sudhir-Agrawal-to-join-as-scientific-advisor.html"),o("Apr 12, 2018","Recruitment completed for phase I/II study with LTX-315","/news/405/130/Recruitment-completed-for-phase-III-study-with-LTX-315.html"),o("Apr 11, 2018",'Lytix Biopharma to present data on "turning COLD Tumors HOT" at AACR 2018',"/news/404/130/Lytix-Biopharma-to-present-data-on-turning-COLD-Tumors-HOT-at-AACR-2018.html"),o("Apr 11, 2018","Lytix Biopharma invited to China together with the Norwegian Minister of Health and Care Services","/news/403/130/Lytix-Biopharma-invited-to-China-together-with-the-Norwegian-Minister-of-Health-and-Care-Services.html"),o("Feb 23, 2018","Interim report Q4 2017 is now available","/news/402/130/Interim-report-Q4-2017-is-now-available.html"),o("Feb 15, 2018","Lytix Biopharma will together with Mikael Pittet present data at AACR","/news/401/130/Lytix-Biopharma-will-together-with-Mikael-Pittet-present-data-at-AACR.html"),o("Jan 30, 2018","Recruitment of patients in the breast cancer arm was strong and is completed","/news/400/130/Recruitment-of-patients-in-the-breast-cancer-arm-was-strong-and-is-completed.html"),o("Jan 9, 2018","Interim report Q3 2017 is available","/news/399/130/Interim-report-Q3-2017-is-available.html"),o("Dec 20, 2017","Lytix Biopharma receives funding for innovation partnership with OncoImmunity in search for neoantigens","/news/398/130/Lytix-Biopharma-receives-funding-for-innovation-partnership-with-OncoImmunity-in-search-for-neoantigens.html"),o("Dec 13, 2017","Dr Andrew Saunders has left Lytix Biopharma","/news/397/130/Dr-Andrew-Saunders-has-left-Lytix-Biopharma.html"),o("Nov 8, 2017","Lytix Biopharma will present two posters at SITC in Washington","/news/396/130/Lytix-Biopharma-will-present-two-posters-at-SITC-in-Washington.html"),o("Nov 1, 2017","Upcoming shareholder meetings in Harstad, Tromsø and Oslo","/news/395/130/Upcoming-shareholder-meetings-in-Harstad-Troms%C3%B8-and-Oslo.html"),o("Oct 17, 2017","Changes to BoD in Lytix Biopharma as part of preparations for the IPO","/news/394/130/Changes-to-BoD-in-Lytix-Biopharma-as-part-of-preparations-for-the-IPO.html"),o("Sep 20, 2017","Lytix among the speakers at Redeye's 'Fight cancer – immune-oncology' conference","/news/393/130/Lytix-among-the-speakers-at-Redeyes-Fight-cancer-immune-oncology-conference.html"),o("Sep 18, 2017","Lytix collaboration with Pittet mentioned in Nature Medicine","/news/392/130/Lytix-collaboration-with-Pittet-mentioned-in-Nature-Medicine.html"),o("Sep 14, 2017","Lytix Biopharma among the speakers at Immuno-Oncology Frontiers in Berlin","/news/391/130/Lytix-Biopharma-among-the-speakers-at-Immuno-Oncology-Frontiers-in-Berlin.html"),o("Sep 7, 2017","Newsletter September 2017","/news/390/130/Newsletter_September-2017.html"),o("Sep 5, 2017","Edwin Klumper - new CEO in Lytix Biopharma","/news/389/130/Edwin-Klumper-new-CEO-in-Lytix-Biopharma.html"),o("Sep 4, 2017","Lytix Biopharma will present two poster at CIMT Sept 8th","/news/388/130/Lytix-Biopharma-will-present-two-poster-at-CIMT-Sept-8th.html"),o("Aug 31, 2017","LTX-315's ability to induce abscopal anticancer activity published in OncoImmunology","/news/386/130/LTX-315s-ability-to-induce-abscopal-anticancer-activity-published-in-OncoImmunology.html"),o("Aug 22, 2017","Norweg

105ian Cancer Society invests in Lytix Biopharma ASA","/news/384/130/Norwegian-Cancer-Society-invests-in-Lytix-Biopharma-ASA.html"),o("Aug 21, 2017","Lytix strengthens the board with clinical development and commercial oncology experience","/news/385/130/Lytix-strengthens-the-board-with-clinical-development-and-commercial-oncology-experience.html"),o("Aug 15, 2017","Lytix Biopharma completes 1st cohort of LTX-315 monotherapy","/news/383/130/Lytix-Biopharma-completes-1st-cohort-of-LTX-315-monotherapy.html"),o("Jul 3, 2017","2nd combination cohort of LTX-315 and pembrolizumab in TNBC completed","/news/381/130/2nd-combination-cohort-of-LTX-315-and-pembrolizumab-in-TNBC-completed.html"),o("Jun 6, 2017","HalioDx SAS, an immuno-oncology diagnostic company, was co-authors at the poster of Phase I data on LTX-315 at ASCO","/news/380/130/HalioDx-SAS-an-immuno-oncology-diagnostic-company-was-size-authors-at-the-poster-of-Phase-I-data-on-LTX-315-at-ASCO.html"),o("Jun 5, 2017","ASCO 2017 - Lytix Biopharma featured in Dagens Medisin","/news/379/130/ASCO-2017-Lytix-Biopharma-featured-in-Dagens-Medisin.html"),o("May 31, 2017","Lytix Biopharma will present poster at ASCO Monday June 5th 2017","/news/378/130/Lytix-Biopharma-will-present-poster-at-ASCO-Monday-June-5t-2017.html"),o("May 24, 2017","Lytix Biopharma held company presentation at BioEquity Europe in Paris","/news/377/130/Lytix-Biopharma-held-company-presentation-at-BioEquity-Europe-in-Paris.html"),o("May 23, 2017","Data on LTX-315 has been accepted for poster presentation at ASCO 2017","/news/376/130/Data-on-LTX-315-has-been-accepted-for-poster-presentation-at-ASCO-2017.html"),o("May 21, 2017","Immunotherapeutic effects of LTX-315 published in Future Medicinal Chemistry","/news/375/130/Immunotherapeutic-effects-of-LTX-315-published-in-Future-Medicinal-Chemistry.html"),o("Apr 21, 2017","Lytix Biopharma completes 1st combination cohort of LTX-315 and pembrolizumab in TNBC","/news/374/130/Lytix-Biopharma-completes-1st-combination-cohort-of-LTX-315-and-pembrolizumab-in-TNBC.html"),o("Apr 21, 2017","Newsletter April 2017","/news/373/130/Newsletter_April-2017.html"),o("Apr 20, 2017","Lytix Biopharma raises in total 80 million NOK","/news/371/130/Lytix-Biopharma-raises-in-total-80-million-NOK.html"),o("Apr 6, 2017","Lytix Biopharma presented 4 posters at AACR in Washington April 2017","/news/370/130/Lytix-Biopharma-presented-4-posters-at-AACR-in-Washington-April-2017.html"),o("Apr 3, 2017","LTX-315 was presented at ICI Boston (a dedicated Cancer Immunotherapy meeting) in March 2017","/news/372/130/LTX-315-was-presented-at-ICI-Boston-a-dedicated-Cancer-Immunotherapy-meeting-in-March-2017.html"),o("Mar 23, 2017","Lytix Biopharma featured in Finansavisen, regarding pre-IPO and IPO","/news/369/130/Lytix-Biopharma-featured-in-Finansavisen-regarding-pre-IPO-and-IPO.html"),o("Mar 20, 2017","The repair share issue in Lytix Biopharma is now launched","/news/368/130/The-repair-share-issue-in-Lytix-Biopharma-is-now-launched.html"),o("Mar 20, 2017","Lytix Biopharma invites shareholders to information meetings in April","/news/367/130/Lytix-Biopharma-invites-shareholders-to-information-meetings-in-April.html"),o("Mar 15, 2017","Lytix Biopharma featured in Mergermarket article","/news/366/130/Lytix-Biopharma-featured-in-Mergermarket-article.html"),o("Mar 8, 2017","Lytix Biopharma presented at the 10th Annual European Life Sciences CEO Forum & Exhibition","/news/365/130/Lytix-Biopharma-presented-at-the-10th-Annual-European-Life-Sciences-CEO-Forum-Exhibition.html"),o("Feb 3, 2017","Lytix Biopharma supports research at Weill 

105Cornell Medicine, New York","/news/364/130/Lytix-Biopharma-supports-research-at-Weill-Cornell-Medicine-New-York.html"),o("Jan 30, 2017","Lytix Biopharma granted 15.9 MNOK from The Research Council of Norway","/news/363/130/Lytix-Biopharma-granted-15.9-MNOK-from-The-Research-Council-of-Norway.html"),o("Jan 13, 2017","Lytix Biopharma announces the appointment of Torbjørn Furuseth as CFO","/news/362/130/Lytix-Biopharma-announces-the-appointment-of-Torbj%C3%B8rn-Furuseth-as-CFO.html"),o("Jan 6, 2017","Lytix Biopharma present at J.P. Morgan 35th Annual Healthcare Conference 2017, in San Francisco","/news/361/130/Lytix-Biopharma-present-at-J.P.-Morgan-35th-Annual-Healthcare-Conference-2017-in-San-Francisco.html"),o("Dec 22, 2016","Lytix enrols first patient in LTX-315/anti-PD1 combination study","/news/360/130/Lytix-enrols-first-patient-in-LTX-315anti-PD1-combination-study.html"),o("Nov 29, 2016","Ongoing financing round","/news/359/130/Ongoing-financing-round.html"),o("Nov 11, 2016","Håkan Wickholm presents Lytix Biopharma at Redeye Life Science Seminar 2016","/news/358/130/H%C3%A5kan-Wickholm-presents-Lytix-Biopharma-at-Redeye-Life-Science-Seminar-2016.html"),o("Oct 19, 2016","Newsletter October 2016","/news/357/130/Newsletter-October-2016.html"),o("Sep 21, 2016","Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors","/news/356/130/Lytix-Biopharma-develops-second-generation-oncolytic-molecules-for-deep-seated-tumors.html"),o("Sep 21, 2016","Håkan Wickholm presents Lytix Biopharma at Sachs Annual Biotech in Europe Forum","/news/355/130/H%C3%A5kan-Wickholm-presents-Lytix-Biopharma-at-Sachs-Annual-Biotech-in-Europe-Forum.html"),o("Sep 20, 2016","LTX-315 presented at Basel Life Science week","/news/353/130/LTX-315-presented-at-Basel-Life-Science-week.html"),o("Sep 15, 2016","Lytix Biopharma present at Nordic Life Science Days in Stockholm Sept 2016","/news/354/130/Lytix-Biopharma-present-at-Nordic-Life-Science-Days-in-Stockholm-Sept-2016.html"),o("Sep 1, 2016","Dr. Pittet at Massachusetts General Hospital and Harvard performs studies with LTX-315","/news/352/130/Dr.-Pittet-at-Massachusetts-General-Hospital-and-Harvard-performs-studies-with-LTX-315.html"),o("Jun 14, 2016","LTX-315 in two oral presentations at WPC in Boston 14-16 June 2016","/news/351/130/LTX-315-in-two-oral-presentations-at-WPC-in-Boston-14-16-June-2016.html"),o("Jun 3, 2016","Lytix Biopharma attends BIO International Convention 2016","/news/350/130/Lytix-Biopharma-attends-BIO-International-Convention-2016.html"),{date:"May 11, 2016",title:"At CIMT 2016 Lytix presented LTX-315's ability to make tumors more T-cell inflamed"},{date:"Apr 27, 2016",title:"Newsletter April 2016"},{date:"Apr 27, 2016",title:"New LTX-315 article published in Cell Death and Differentiation"},{date:"Apr 27, 2016",title:"Lytix Biopharma will do a presentation at BioEquity Europe in Copenhagen in May"},{date:"Apr 25, 2016",title:"Immunotherapy works on a growing number of cancer types"},{date:"Apr 15, 2016",title:"Lytix Biopharma presented 4 posters at AACR in New Orleans April 2016"},{date:"Mar 30, 2016",title:"The story behind the discovery of LTX-315 published in Journal of Medicinal Chemistry"},{date:"Mar 21, 2016",title:"A positive editorial discussion on LTX-315's mode of action in the journal Cell Cycle"},{date:"Mar 15, 2016",title:"New LTX-315 paper in Cell Differentiation and Cell Cycle"},{date:"Mar 2, 2016",title:"Death of Prof. Holbrook Kohrt, SAB member"},{date:"Mar 1, 2016",title:"Håkan Wickholm new CEO, acting, in Lytix Biopharma"},{date:"Feb 28, 2016",title:"Lytix Biopharma is among promising cancer biotech companies featured in Norwegian article"},{date:"Feb 22, 2016",title:"Bent Høie, Minister of Health, killed cancer cells with LTX-315"},{date:"Feb 11, 2016",title:"Lytix Biopharma featured in article about collaboration in OCC Incubator"},{date:"Jan 21, 2016",title:"In a difficult marked, Lytix had a successful share issue - read article in DN"},{date:"Jan 12, 2016",title:"See the new video presentation of LTX-315 - its development and MoA"},{date:"Dec 22, 2015",title:"Lytix Biopharma granted patent in the US"}

105,{date:"Dec 15, 2015",title:"Lytix Biopharma raises approximately 80 million NOK"},{date:"Nov 23, 2015",title:"Issuing of new shares in Lytix Biopharma, the subscription deadline is December 10, 2015"},{date:"Nov 16, 2015",title:"LTX-315 development history presented at European peptide conference"},{date:"Nov 11, 2015",title:"Lytix Biopharma in one of The 10 Hottest Bioincubators in Europe"},{date:"Nov 9, 2015",title:"Lytix Biopharma presented LTX-315 at melanoma conference in Rome"},{date:"Nov 2, 2015",title:"Newsletter November 2015"},{date:"Nov 2, 2015",title:"Lytix Biopharma announces prominent Scientific and Clinical Advisory Board"},{date:"Oct 31, 2015",title:"Lytix Biopharma shelves clinical trial with LTX-109 in diabetic foot ulcers"},{date:"Oct 16, 2015",title:"A new paper with LTX-315 published in Oncotarget"},{date:"Sep 28, 2015",title:"TV lecture on antibacterial compounds by one of Lytix Biopharma's founders"},{date:"Sep 26, 2015",title:"Lytix Biopharma presented initial results from LTX-315 Phase I study at ECC2015"},{date:"Sep 21, 2015",title:"LTX-315 paper published in Oncotarget"},{date:"Sep 9, 2015",title:"Lytix Biopharma in panel discussion at Nordic Life Science Days in Stockholm Sept 9th 2015"},{date:"Sep 9, 2015",title:"Political seminar on knowledge-based reorganization to new growth and value creation"},{date:"Aug 25, 2015",title:"Lytix Biopharma's preclinical activity moves into OCCI"},{date:"Jun 22, 2015",title:"Lytix Biopharma presents poster at Melanoma Conference in Reykjavik"},{date:"Jun 15, 2015",title:"Lytix Biopharma attends BIO International Convention 2015"},{date:"Jun 12, 2015",title:"Lytix Biopharma announces Gert W. Munthe as new Chairman of the Board"},{date:"Jun 10, 2015",title:"Newsletter June 2015"},{date:"Jun 1, 2015",title:"Lytix Biopharma represented and interviewed at ASCO in Chicago"},{date:"May 13, 2015",title:"Lytix Biopharma invited to speak at Scandinavian Sarcoma group meeting in Stockholm"},{date:"Apr 24, 2015",title:"Lytix Biopharma announces a Proof of Concept milestone for LTX-315"},{date:"Apr 23, 2015",title:"Lytix Biopharma presented at Anglonordic Life Science Conference XII in London"},{date:"Apr 21, 2015",title:"Lytix Biopharma at AACR with poster"},{date:"Mar 11, 2015",title:"Research and innovation in interest of the patient"},{date:"Mar 9, 2015",title:"Lytix Biopharma attends BIO-Europe Spring 2015 in Paris"},{date:"Mar 3, 2015",title:"New collaboration period with Institut Gustave Roussy"},{date:"Mar 3, 2015",title:"Newsletter March 2015"},{date:"Mar 2, 2015",title:"Lytix Biopharma presented at Arctic Securities' Biotech Seminar"},{date:"Feb 18, 2015",title:"Lytix Biopharma presented at Bioprosp_15 in Tromsø February 18th"},{date:"Feb 5, 2015",title:"Lytix Biopharma featured in 'Norsk Industris Konjunkturrapport 2015'"},{date:"Dec 22, 2014",title:"NOK 50 million raised in Lytix Biopharma"},{date:"Dec 2, 2014",title:"Listing of new shares in Lytix Biopharma, the subscription deadline is December 17, 2014"},{date:"Nov 21, 2014",title:"Lytix Biopharma appoints Andrew Saunders, M.D., FFPM as Chief Medical Officer"},{date:"Nov 10, 2014",title:"Lytix Biopharma attended SITC in Washington Nov 6-9, 2014"},{date:"Oct 31, 2014",title:"'New star' – Lytix Biopharma recognized in Aftenposten"},{date:"Oct 29, 2014",title:"New article about LTX-109 published in 'Antimicrobial Agents and Chemotherapy'"},{date:"Oct 16, 2014",title:"Extension of the order period for placement in Lytix Amicoat AS"},{date:"Oct 9, 2014",title:"In his speech Oct 8th Minister Røe Isaksen put Lytix Biopharma forward as a good example"},{date:"Sep 24, 2014",title:"Lytix Biopharma got honored guests - NoMA Tuesday and two ministers Wednesday"},{date:"Sep 20, 2014",title:"CSO Øystein Rekdal invited as guest speaker at Karolinska"},{date:"Sep 19, 2014",title:"Lytix Biopharma attends ESMO in Madrid, Spain, Sept. 26-30, 2014"},{date:"Sep 10, 2014",title:"Newsletter September 2014"},{date:"Sep 9, 2014",title:"Lytix Biopharma awarded this year's Nordic Stars Awards"},{date:"Sep 8, 2014",title:"Impetigo data presented at ICAAC, Washington D.C., Sep 6th"},{date:"Sep 5, 2014",title:"LTX-315's ability to cure B61 melanomas is published in two international journals"},{date:"Sep 3, 2014",title:"Lytix Biopharma focuses on immuno-oncology future"},{date:"Aug 18, 2014",title:"Lytix Biopharma attends Nordic Life Science Days in Stockholm September 7-9, 2014"},{date:"Jul 7, 2014",title:"Gert Munthe and Kari Dyvik joins the Board of Directors in Lytix Biopharma"},{date:"Jun 23, 2014",title:"Lytix Biopharma attends BIO International Convention 2014"},{date:"Jun 10, 2014",title:"Lytix Biopharma starts subsidiary within antimicrobial coating - Lytix Amicoat"},{date:"Jun 6, 2014",title:"Dr. Line presents LTX-315 data at International Liver Transplantation Society congress in London"},{date:"Jun 2, 2014",title:"Lytix Biopharma featured in media after presentation at ASCO"},{date:"Jun 1, 2014",title:"June 1st Lytix Biopharma presented data at ASCO from the first LTX-315 clinical trial"},{date:"May 28, 2014",title:"Lytix Biopharma extends the research collaboration with Institute Gustave Roussy"},{date:"May 22, 2014",title:"Lytix Biopharma features in 'Health Industry Conference' appendix"},{date:"May 20, 2014",title:"Newsletter May 2014"}

105,{date:"May 6, 2014",title:"Lytix Biopharma enters into partnership dialogue about further development of LTX-109"},{date:"Apr 30, 2014",title:"Lytix Biopharma is attending Association for Cancer Immunotherapy (CIMT) meeting"},{date:"Apr 25, 2014",title:"Lytix Biopharma featured in Finansavisen regarding Pharmasum Therapeutics"},{date:"Apr 16, 2014",title:"'Tromsø company attracts attention at cancer congress' - article in iTromsø"},{date:"Apr 10, 2014",title:"Lytix Biopharma starts a new company within treatment of dementia, Pharmasum Therapeutics"},{date:"Apr 7, 2014",title:"Lytix Biopharma at AACR with 3 posters"},{date:"Mar 31, 2014",title:"Lytix Biopharma published new promising results with LTX-315"},{date:"Feb 28, 2014",title:"Extraordinary general assembly and shareholder meetings in Lytix Biopharma in March"},{date:"Feb 5, 2014",title:"Lytix Biopharma presented in economic report from the Norwegian Industry"},{date:"Feb 1, 2014",title:"Newsletter February 2014"},{date:"Jan 29, 2014",title:"Lytix Biopharma has been granted BIA funding for the cancer project (LTX-315)"},{date:"Dec 5, 2013",title:"Successful share issue featured in media"},{date:"Dec 4, 2013",title:"NOK 50 million subscribed in Lytix Biopharma"},{date:"Nov 27, 2013",title:"First patient in new cancer study featured in media"},{date:"Nov 26, 2013",title:"Lytix Biopharma included first patient in a new cancer study"},{date:"Nov 25, 2013",title:"John Sigurd Svendsen from Lytix Biopharma featured in Altaposten"},{date:"Nov 22, 2013",title:"Øystein Rekdal from Lytix Biopharma presents at 'Gazelle conference' in Tromsø Monday"},{date:"Nov 20, 2013",title:"Lytix Biopharma's drug candidate LTX-315 presented at AASLD in Washington"},{date:"Nov 19, 2013",title:"Lytix Biopharma's antimicrobial drug candidate LTX-109 is one of 'Top Projects To Watch'"},{date:"Nov 15, 2013",title:"Lytix Biopharma featured in Harstad Tidende"},{date:"Nov 13, 2013",title:"Norwegian cancer medicine presented at the world's largest liver congress"},{date:"Nov 8, 2013",title:"Lytix Biopharma receives Oslo Cancer Cluster immuno-oncology grant"},{date:"Oct 29, 2013",title:"Invitation to shareholder meetings"},{date:"Oct 18, 2013",title:"Listing of new shares in Lytix Biopharma. Minimum investment NOK 820 000."},{date:"Oct 17, 2013",title:"Lytix Biopharma featured several times in Nordic press"},{date:"Oct 17, 2013",title:"Lytix Biopharma featured in iTromsø"},{date:"Oct 16, 2013",title:"Unni Hjelmaas interviewed in Dagens Næringsliv, 'På nattbordet'"},{date:"Oct 15, 2013",title:"LTX-315 is approved for a new exploratory phase I study in Europe"},{date:"Oct 15, 2013",title:"Lytix Biopharma 'blast' cancer cells in minutes - article in VG"},{date:"Oct 14, 2013",title:"Lytix Biopharma featured in Norwegian press, Dagens Næringsliv"},{date:"Oct 1, 2013",title:"Newsletter October 2013"},{date:"Sep 27, 2013",title:"Lytix Biopharma attended the 21st ECDO conference in Paris with poster"},{date:"Sep 16, 2013",title:"Lytix Biopharma attended ICAAC 2013, in Denver Colorado"},{date:"Sep 2, 2013",title:"Disputas - Sivilingeniør Ketil André Camilio"},{date:"Aug 20, 2013",title:"Lytix Biopharma attended the 53rd ICAAC annual meeting, 10-13 September in Denver, Colorado"},{date:"Aug 6, 2013",title:"Lytix Biopharma in Aftenposten"},{date:"Aug 2, 2013",title:"Lytix Biopharma featured in Norwegian financial press, Finansavisen"},{date:"Jul 15, 2013",title:"'Tromsø company with startling cancer findings', article in Nordlys"},{date:"Jul 15, 2013",title:"TV2 news coverage about Lytix Biopharma"}

105,{date:"Jun 17, 2013",title:"LTX-315 kills cancer cells in minutes, article in Dagens Næringsliv"},{date:"Jun 1, 2013",title:"Newsletter June 2013"},{date:"May 30, 2013",title:"Lytix Biopharma attended ASCO (American Society of Clinical Oncology) annual meeting 2013"},{date:"May 6, 2013",title:"Lytix Biopharma attended CIMT (Cancer Immunotherapy) annual meeting 2013"},{date:"Apr 12, 2013",title:"Shareholder meeting in Harstad April 18th 2013"},{date:"Apr 9, 2013",title:"Lytix Biopharma attends BIO International Convention 2013"},{date:"Apr 8, 2013",title:"Lytix Biopharma attended the American Association for Cancer Research (AACR) annual meeting"},{date:"Apr 3, 2013",title:"Lytix Biopharma's infection drug candidate has the potential to treat and prevent skin infections"},{date:"Feb 22, 2013",title:"Lytix Biopharma enrolls first patient in LTX-109 Phase II PoC infection study"},{date:"Nov 22, 2012",title:"Shareholder meetings now finalized"},{date:"Nov 7, 2012",title:"Lytix Biopharma in Aftenposten"},{date:"Nov 2, 2012",title:"LTX-109 featured in newspaper article on antibiotic resistance in A-magasinet"},{date:"Oct 30, 2012",title:"Lytix Biopharma and ABG Sundal Collier signs collaboration agreement"},{date:"Oct 29, 2012",title:"Invitation to shareholder meeting"},{date:"Oct 23, 2012",title:"Strategy meeting in Lytix Biopharma"},{date:"Oct 15, 2012",title:"Lytix Biopharma in one of the leading business newspapers in Norway"},{date:"Aug 30, 2012",title:"Government grant and share emission"},{date:"Jul 5, 2012",title:"Future by Semcon presenting Lytix Biopharma and Lytixar in the article 'Antibiotics of the future'"},{date:"May 31, 2012",title:"LTX-315 presented at the 2012 GAP Conference in Oslo in May"},{date:"May 15, 2012",title:"Procedures for shareholder information"},{date:"Feb 28, 2012",title:"Unni Hjelmaas has been appointed new CEO of Lytix Biopharma ASA"},{date:"Oct 11, 2011",title:"ICAAC 2011"},{date:"May 26, 2011",title:"Successful Proof of Concept for topical antimicrobial drug Lytixar (LTX-109)"},{date:"Dec 23, 2010",title:"Lytix Biopharma closes successful shares emission"},{date:"Dec 6, 2010",title:"Lytix Biopharma and KAELGemVax announce first patient treated in clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy"},{date:"Sep 1, 2010",title:"Lytix Biopharma ASA announces approval by Hungarian authorities and ethics committee to start Phase IIa clinical trial with Lytixar (LTX-109) in Gram positive skin infections"},{date:"Jun 9, 2010",title:"Lytix Biopharma and KAELGemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy"},{date:"May 20, 2010",title:"Lytix Biopharma ASA announces regulatory approval by Swedish authorities to commence Phase I/IIa clinical trial with Lytixar (LTX-109) in MRSA"},{date:"May 20, 2010",title:"Lytix Biopharma ASA update on phase I progress with Oncopore for solid tumours"},{date:"Dec 14, 2009",title:"Lytix Biopharma ASA announces regulatory approval by Norwegian and Swedish authorities to commence Phase I clinical trial of Oncopore™ (LTX-315) in cancer"},{date:"Sep 23, 2009",title:"Lytix Biopharma presented new data on antimicrobial drug Lytixar™ (LTX-109) at ICAAC"},{date:"Aug 19, 2009",title:"Lytix Biopharma announces start of dosing in Phase I trial"},{date:"Jun 18, 2009",title:"Lytix Biopharma and KAELGemVax announce joint clinical trial to combine LTX-315 and GV1001 cancer immunotherapy"},{date:"Jun 2, 2009",title:"Additional funding through shares emission and warrant scheme"},{date:"Mar 24, 2009",title:"Additional funding through shares emission and warrant scheme"},{date:"Feb 26, 2009",title:"Lytix Biopharma to expand team of drug development professionals"},{date:"Jan 21, 2009",title:"Lytix Biopharma closes successful funding round"}].map((e,t)=>({...e,href:`/news/article/${t}`})),l={"https://newsweb.oslobors.no/message/674993":"Jun 1, 2026"};function h(e){return new Date(e).toLocaleDateString("en-US",{month:"short",day:"numeric",year:"numeric",timeZone:"America/Los_Angeles"})}function c(e){if(null!=e.publishedAtMs)return e.publishedAtMs;let t=Date.parse(e.date+" 12:00:00 GMT+0100");return Number.isNaN(t)?0:t}let d=[{publishedAtMs:1788440559e3,date:"Sep 3, 2026",category:"Corporate",title:"Lytix Biopharma ASA: Grant of share options to management and key personnel",link:"https://newsweb.oslobors.no/message/681627"},{publishedAtMs:1788379297e3,date:"Sep 2, 2026",category:"Corporate",title:"Lytix Biopharma ASA: Mandatory notification of trade by primary insider",link:"https://newsweb.oslobors.no/message/681499"},{publishedAtMs:17878068e5,date:"Aug 26, 2026",category:"Clinical",title:"Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone",link:"https://newsweb.oslobors.no/message/680938"},{publishedAtMs:17878065e5,date:"Aug 26, 2026",category:"Clinical",title:"FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma",link:"https://newsweb.oslobors.no/message/680926"},{publishedAtMs:1787756512e3,date:"Aug 26, 2026",category:"Clinical",title:"Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Comb

105ination with Ipilimumab and Nivolumab in Early-stage Resectable Melanoma",link:"https://newsweb.oslobors.no/message/680896"},{publishedAtMs:17872902e5,date:"Aug 20, 2026",category:"Corporate",title:"Lytix Biopharma: Invitation to the Q2 2026 Results Presentation",link:"https://newsweb.oslobors.no/message/680439"},{publishedAtMs:1787041814e3,date:"Aug 18, 2026",category:"Corporate",title:"Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer",link:"https://newsweb.oslobors.no/message/680062"},{publishedAtMs:1784808936e3,date:"Jul 23, 2026",category:"Corporate",title:"Lytix Biopharma ASA: Grant of share options to management and key personnel",link:"https://newsweb.oslobors.no/message/678616"},{publishedAtMs:1780290312e3,date:"Jun 1, 2026",category:"Clinical",title:"Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab",link:"https://newsweb.oslobors.no/message/674993"},{publishedAtMs:17793396e5,date:"May 20, 2026",category:"Clinical",title:"Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances",link:"https://newsweb.oslobors.no/message/674055"},{publishedAtMs:1778832981e3,date:"May 15, 2026",category:"Corporate",title:"Lytix Biopharma: Invitation to the Q1 2026 Results Presentation",link:"https://newsweb.oslobors.no/message/673590"},{publishedAtMs:17780436e5,date:"May 5, 2026",category:"Clinical",title:"New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma",link:"https://newsweb.oslobors.no/message/672456"},{publishedAtMs:177678e7,date:"Apr 21, 2026",category:"Clinical",title:"Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026",link:"https://newsweb.oslobors.no/message/671107"},{publishedAtMs:17767476e5,date:"Apr 20, 2026",category:"Clinical",title:"Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma",link:"https://newsweb.oslobors.no/message/671007"},{publishedAtMs:177637431e4,date:"Apr 16, 2026",category:"Corporate",title:"Lytix Biopharma ASA - Conversion to public limited liability company and name change registered",link:"https://newsweb.oslobors.no/message/670832"},{publishedAtMs:1776179263e3,date:"Apr 14, 2026",category:"Corporate",title:"Lytix Biopharma AS: Minutes from Annual General Meeting",link:"https://newsweb.oslobors.no/message/670597"},{publishedAtMs:177576074e4,date:"Apr 9, 2026",category:"Corporate",title:"Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS",link:"https://newsweb.oslobors.no/message/670327"},{publishedAtMs:17755812e5,date:"Apr 7, 2026",category:"Corporate",title:"Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth",link:"https://newsweb.oslobors.no/message/670009"},{publishedAtMs:1774426499e3,date:"Mar 25, 2026",category:"Corporate",title:"Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026",link:"https://newsweb.oslobors.no/message/669252"},{publishedAtMs:1774332234e3,date:"Mar 23, 2026",category:"Financial",title:"Lytix Biopharma AS: Annual Report for 2025",link:"https://newsweb.oslobors.no/message/669137"},{publishedAtMs:17738136e5,date:"Mar 17, 2026",category:"Clinical",title:"Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026",link:"https://newsweb.oslobors.no/message/668636"},{publishedAtMs:1771931773e3,date:"Feb 24, 2026",category:"Corporate",title:"Lytix Biopharma AS - New share capital registered",link:"https://newsweb.oslobors.no/message/666562"},{publishedAtMs:1771314569e3,date:"Feb 16, 2026",category:"Scientific",title:"Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)",link:"https://newsweb.oslobors.no/message/666019"},{publishedAtMs:1770876e6,date:"Feb 11, 2026",category:"Financial",title:"Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report",link:"https://newsweb.oslobors.no/message/665487"},{publishedAtMs:1770746657e3,date:"Feb 10, 2026",category:"Corporate",title:"Lytix Biopharma AS - Final result of Subsequent Offering and allocation of Offer Shares",link:"https://newsweb.oslobors.no/message/665317"},{publishedAtMs:17707032e5,date:"Feb 9, 2026",category:"Corporate",title:"Lytix Biopharma AS - Last day of the Subscription Period in the Subsequent Offering",link:"https://newsweb.oslobors.no/message/665211"},{publishedAtMs:1770290202e3,date:"Feb 5, 2026",category:"Corporate",title:"Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report",link:"https://newsweb.oslobors.no/message/664929"},{publishedAtMs:1769507388e3,date:"Jan 27, 2026",category:"Corporate",title:"Lytix Biopharma AS - Publication of Prospectus regarding Subsequent Offering and commencement of Subscription Period",link:"https://newsweb.oslobors.no/message/664260"},{publishedAtMs:1769445168e3,date:"Jan 26, 2026",category:"Corporate",title:"Lytix Biopharma AS - EGM minutes - Subsequent Offering, ASA Conversion, Board Expansion and Board Authorization Approved",link:"https://newsweb.oslobors.no/message/664224"},{publishedAtMs:1768406909e3,date:"Jan 14, 2026",category:"Corporate",title:"Lytix Biopharma AS - New share capital registered",link:"https://newsweb.oslobors.no/message/663627"},{publishedAtMs:176821513e4,date:"Jan 12, 2026",category:"Corporate",title:"Lytix Biopharma AS - Notice of extraordinary general meeting 26 January 2026",link:"https://newsweb.oslobors.no/message/663462"},{publishedAtMs:1767824083e3,date:"Jan 7, 2026",category:"Financial",title:"Finansiell kalender",link:"https://newsweb.oslobors.no/message/663247"},{publishedAtMs:1767824083e3,date:"Jan 7, 2026",category:"Financial",title:"Financial calendar",link:"https://newsweb.oslobors.no/message/663248"},{publishedAtMs:1765456786e3,date:"Dec 11, 2025",category:"Corporate",title:"LYTIX BIOPHARMA AS - MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER",link:"https://newsweb.oslobors.no/message/661716"},{publishedAtMs:17634456e5,date:"Nov 17, 2025",category:"Clinical",title:"Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy",link:"https://newsweb.oslobors.no/message/659896"},{publishedAtMs:17631e8,date:"Nov 13, 2025",category:"Corporate",title:"Lytix Biopharma: Invitation to Q3 2025 Results Presentation",link:"https://newsweb.oslobors.no/message/659688"},{publishedAtMs:17628408e5,date:"Nov 10, 2025",category:"Corporate",title:"Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet",link:"https://newsweb.oslobors.no/message/659270"},{publishedAtMs:17628408e5,date:"Nov 10, 2025",category:"Clinical",title:"Lytix Biopharma Announce

105s Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital",link:"https://newsweb.oslobors.no/message/659271"},{publishedAtMs:17627544e5,date:"Nov 9, 2025",category:"Clinical",title:"New Phase II Study Data from Lytix Biopharma's Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide",link:"https://newsweb.oslobors.no/message/659147"},{publishedAtMs:1760089571e3,date:"Oct 10, 2025",category:"Financial",title:"Finansiell kalender",link:"https://newsweb.oslobors.no/message/656980"},{publishedAtMs:1760089571e3,date:"Oct 10, 2025",category:"Financial",title:"Financial calendar",link:"https://newsweb.oslobors.no/message/656981"},{publishedAtMs:17598996e5,date:"Oct 7, 2025",category:"Clinical",title:"Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025",link:"https://newsweb.oslobors.no/message/656799"},{publishedAtMs:1756749066e3,date:"Sep 1, 2025",category:"Corporate",title:"Lytix Biopharma AS: Grant of share options to management and key personnel",link:"https://newsweb.oslobors.no/message/654449"},{publishedAtMs:17563572e5,date:"Aug 27, 2025",category:"Clinical",title:"Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization",link:"https://newsweb.oslobors.no/message/654030"},{publishedAtMs:1755777231e3,date:"Aug 21, 2025",category:"Corporate",title:"Lytix Biopharma: Invitation to Q2 2025 Results Presentation",link:"https://newsweb.oslobors.no/message/653556"},{publishedAtMs:1747836302e3,date:"May 21, 2025",category:"Corporate",title:"Lytix Biopharma AS: GRANT OF SHARE OPTIONS",link:"https://newsweb.oslobors.no/message/647082"},{publishedAtMs:17472852e5,date:"May 14, 2025",category:"Clinical",title:"Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress",link:"https://newsweb.oslobors.no/message/646408"},{publishedAtMs:17467668e5,date:"May 8, 2025",category:"Corporate",title:"Lytix Biopharma: Invitation to Q1 2025 Results Presentation",link:"https://newsweb.oslobors.no/message/645860"},{publishedAtMs:174592919e4,date:"Apr 29, 2025",category:"Corporate",title:"Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors",link:"https://newsweb.oslobors.no/message/644732"},{publishedAtMs:1745349496e3,date:"Apr 22, 2025",category:"Corporate",title:"Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair",link:"https://newsweb.oslobors.no/message/644086"},{date:"Nov 21, 2024",category:"Partnership",title:"Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion",link:"https://newsweb.oslobors.no/message/632926"},{date:"Nov 18, 2024",category:"Clinical",title:"Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization",link:"https://newsweb.oslobors.no/message/632574"},{date:"Nov 12, 2024",category:"Corporate",title:"Lytix Biopharma: Invitation to Q3 2024 Results Presentation",link:"https://newsweb.oslobors.no/message/631916"},{date:"Nov 06, 2024",category:"Clinical",title:"Lovende fase II-studie i pasienter med tidligfase føflekkreft startet opp ved Radiumhospitalet - første pasient behandlet med Lytix' kreftbehandling",link:"https://newsweb.oslobors.no/message/631412"},{date:"Nov 06, 2024",category:"Clinical",title:"First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma",link:"https://newsweb.oslobors.no/message/631413",featured:!0},{date:"Nov 04, 2024",category:"Partnership",title:"Lytix Biopharma - Oppdatering fra lisensieringspartner Verrica Pharmaceuticals",link:"https://newsweb.oslobors.no/message/631207"},{date:"Nov 04, 2024",category:"Partnership",title:"Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals",link:"https://newsweb.oslobors.no/message/631208"},{date:"Oct 31, 2024",category:"Financial",title:"Financial calendar",link:"https://newsweb.oslobors.no/message/630984"},{date:"Oct 31, 2024",category:"Financial",title:"Finansiell kalender",link:"https://newsweb.oslobors.no/message/630983"}].sort((e,t)=>

105c(t)-c(e));d.slice(0,3);var m=e.i(357071),p=e.i(288498);function u(){let[e,o]=(0,n.useState)("press"),[c,u]=(0,n.useState)(20),[y,g]=(0,n.useState)(20),{items:w}=function(){let[e,t]=(0,n.useState)(d),[a,i]=(0,n.useState)(!0);return(0,n.useEffect)(()=>{let e=!0;return fetch("/api/press-releases").then(e=>{if(!e.ok)throw Error(String(e.status));return e.json()}).then(a=>{e&&a.length>0&&t(a)}).catch(()=>{}).finally(()=>{e&&i(!1)}),()=>{e=!1}},[]),(0,n.useMemo)(()=>({items:e,loading:a}),[e,a])}(),{data:f}=function(){let[e,t]=(0,n.useState)([]),[a,i]=(0,n.useState)(!0);return(0,n.useEffect)(()=>{let e=!0;return async function(){try{let a=await m.client.fetch(p.NEWS_ENTRIES_QUERY);if(!e)return;t(a??[])}catch{if(!e)return;t([])}finally{e&&i(!1)}}(),()=>{e=!1}},[]),(0,n.useMemo)(()=>({data:e,loading:a}),[e,a])}();(0,n.useEffect)(()=>{let e=()=>{let e=window.location.hash.replace("#","");"other-news"===e?o("other"):"press-releases"===e&&o("press")};return e(),window.addEventListener("hashchange",e),()=>window.removeEventListener("hashchange",e)},[]);let x=(0,n.useMemo)(()=>w.map((e,t)=>{var a;let i,n;return{id:`local-press-${t}`,title:e.title,dateLabel:(i=l[e.link])||(null!=e.publishedAtMs?h(e.publishedAtMs):e.date),dateTs:e.publishedAtMs??(a=e.date,Number.isNaN(n=Date.parse(`${a} 12:00:00 GMT+0100`))?0:n),href:e.link,external:!0}}),[w]),b=(0,n.useMemo)(()=>s.map((e,t)=>{let a;return{id:`local-other-${t}`,title:e.title,dateLabel:e.date,dateTs:Number.isNaN(a=Date.parse(e.date))?0:a,href:`/news/article/${t}`,external:!1}}),[]),L=(0,n.useMemo)(()=>f.filter(e=>(e.category??"press_release")==="press_release").map(e=>({id:`sanity-press-${e._id}`,title:e.title,dateLabel:h(new Date(e.publishDate).getTime()),dateTs:new Date(e.publishDate).getTime(),href:e.hasBody&&e.slug?`/news/${e.slug}`:e.pdfUrl||e.externalUrl||"/news",external:!(e.hasBody&&e.slug)})),[f]),v=(0,n.useMemo)(()=>f.filter(e=>"other_news"===e.category).map(e=>({id:`sanity-other-${e._id}`,title:e.title,dateLabel:h(new Date(e.publishDate).getTime()),dateTs:new Date(e.publishDate).getTime(),href:e.hasBody&&e.slug?`/news/${e.slug}`:e.pdfUrl||e.externalUrl||"/news",external:!(e.hasBody&&e.slug)})),[f]),B=(0,n.useMemo)(()=>[...x,...L].sort((e,t)=>t.dateTs-e.dateTs),[x,L]),A=(0,n.useMemo)(()=>[...b,...v].sort((e,t)=>t.dateTs-e.dateTs),[b,v]),C=B.slice(0,c),S=A.slice(0,y);return(0,t.jsxs)("div",{className:"min-h-screen bg-white text-lytix-navy",children:[(0,t.jsxs)("main",{className:"relative z-[2]",children:[(0,t.jsxs)("header",{className:"relative min-h-[280px] md:min-h-[320px] flex items-stretch overflow-hidden border-b border-lytix-ice/80",children:[(0,t.jsxs)("div",{className:"absolute inset-0",children:[(0,t.jsx)(a.default,{src:"/images/lytix ribbon 2.webp",alt:"Lytix Biopharma news",fill:!0,className:"object-cover object-center",priority:!0,quality:90}),(0,t.jsx)("div",{className:"absolute inset-0 bg-gradient-to-r from-white/95 via-white/80 to-white/40"}),(0,t.jsx)("div",{className:"absolute left-0 top-0 bottom-0 w-1.5 bg-lytix-teal md:w-2","aria-hidden":!0})]}),(0,t.jsx)("div",{className:"container relative z-10 mx-auto px-4 lg:px-8 flex items-center py-16 md:py-24",children:(0,t.jsxs)("h1",{className:"text-4xl md:text-6xl font-bold tracking-tight text-[#40525C] drop-shadow-sm",children:[(0,t.jsx)("span",{className:"text-lytix-navy/80",children:"News"}),(0,t.jsx)("span",{className:"text-lytix-navy/80 font-normal",children:" | "}),(0,t.jsx)("span",{className:"text-[#40525C]",children:"Press releases & other news"})]})})]}),(0,t.jsx)("div",{className:"container mx-auto px-4 lg:px-8 py-10 md:py-14 max-w-6xl",children:(0,t.jsxs)("div",{className:"flex flex-col lg:flex-row gap-10 lg:gap-14",children:[(0,t.jsxs)("aside",{className:"lg:w-[220px] shrink-0 lg:border-r border-lytix-ice lg:pr-8",children:[(0,t.jsx)("p",{className:"text-[11px] font-bold uppercase tracking-[0.2em] text-lytix-navy/85 mb-5",children:"News"}),(0,t.jsxs)("nav",{className:"space-y-4 text-sm",children:[(0,t.jsx)("a",{href:"#press-releases",onClick:()=>o("press"),className:"block text-lytix-teal font-semibold leading-snug hover:underline",children:"> Press releases & other news"}),(0,t.jsx)("a",{href:"mailto:[email protected]?subject=Subscribe%20to%20news",className:"block text-lytix-navy/90 leading-snug hover:text-lytix-teal",children:"> Subscribe"})]})]}),(0,t.jsxs)("div",{className:"flex-1 min-w-0 space-y-8 md:space-y-10",children:[(0,t.jsxs)("div",{className:"flex w-full max-w-xl border border-lytix-navy rounded-sm overflow-hidden",role:"tablist","aria-label":"News feed type",children:[(0,t.jsx)("button",{type:"button",role:"tab","aria-selected":"press"===e,id:"tab-press",className:`flex-1 px-4 py-3 text-center text-xs font-bold uppercase tracking-[0.12em] transition-colors ${"press"===e?"bg-lytix-navy text-white":"bg-white text-lytix-navy hover:bg-lytix-ice/40"}`,onClick:()=>{o("press"),window.history.replaceState(null,"","#press-releases")},children:"Press releases"}),(0,t.jsx)("button",{type:"button",role:"tab","aria-selected":"other"===e,id:"tab-other",className:`flex-1 px-4 py-3 text-center text-xs font-bold uppercase tracking-[0.12em] border-l border-lytix-navy transition-colors ${"other"===e?"bg-lytix-navy text-white":"bg-white text-lytix-navy hover:bg-lytix-ice/40"}`,onClick:()=>{o("other"),window.history.replaceState(null,"","#other-news")},children:"Other news"})]}),(0,t.jsxs)("section",{id:"press-releases",className:`scroll-mt-24 ${"press"===e?"block":"hidden"}`,role:"tabpanel","aria-labelledby":"tab-press",children:[(0,t.jsx)("h2",{className:"sr-only",children:"Press releases"}),(0,t.jsx)("ul",{className:"divide-y divide-lytix-ice border-t border-lytix-ice",children:C.map(e=>(0,t.jsxs)("li",{className:"py-5 md:py-6",children:[(0,t.jsx)("p",{className:"text-xs text-lytix-navy/75 mb-2 tabular-nums",children:e.dateLabel}),e.external?(0,t.jsxs)("a",{href:e.href,target:"_blank",rel:"noopener noreferrer",className:"group block",children:[(0,t.jsx)("span",{className:"text-base md:text-lg font-medium text-lytix-teal group-hover:underline leading-snug",children:e.title}),(0,t.jsxs)("span",{className:"mt-2 flex items-center gap-1.5 text-sm text-lytix-navy/80 group-hover:text-lytix-teal",children:["Read more...",(0,t.jsx)(r.ExternalLink,{className:"size-3.5 opacity-70"})]})]}):(0,t.jsxs)(i.default,{href:e.href,className:"group block",children:[(0,t.jsx)("span",{className:"text-base md:text-lg font-medium text-lytix-teal group-hover:underline leading-snug",children:e.title}),(0,t.jsx)("span",{className:"mt-2 block text-sm text-lytix-navy/80 group-hover:text-lytix-teal",children:"Read more..."})]})]},e.id))}),c<B.length&&(0,t.jsx)("div",{className:"mt-8 text-center",children:(0,t.jsx)("button",{type:"button",onClick:()=>u(e=>Math.min(e+40,B.length)),className:"text-sm font-semibold text-lytix-teal hover:underline uppercase tracking-wider",children:"Load more"})})]}),(0,t.jsxs)("section",{id:"other-news",className:`scroll-mt-24 ${"other"===e?"block":"hidden"}`,role:"tabpanel","aria-labelledby":"tab-other",children:[(0,t.jsx)("h2",{className:"sr-only",children:"Other news"}),(0,t.jsx)("ul",{className:"divide-y divide-lytix-ice border-t border-lytix-ice",children:S.map(e=>(0,t.jsxs)("li",{className:"py-5 md:py-6",children:[(0,t.jsx)("p",{className:"text-xs text-lytix-navy/75 mb-2 tabular-nums",children:e.dateLabel}),e.external?(0,t.jsxs)("a",{href:e.href,target:"_blank",rel:"noopener noreferrer",className:"group block",children:[(0,t.jsx)("span",{className:"text-base md:text-lg font-medium text-lytix-teal group-hover:underline leading-snug",children:e.title}),(0,t.jsxs)("span",{className:"mt-2 flex items-center gap-1.5 text-sm text-lytix-navy/80 group-hover:text-lytix-teal",children:["Read more...",(0,t.jsx)(r.ExternalLink,{className:"size-3.5 opacity-70"})]})]}):(0,t.jsxs)(i.default,{href:e.href,className:"group block",children:[(0,t.jsx)("span",{className:"text-base md:text-lg font-medium text-lytix-teal group-hover:underline leading-snug",children:e.title}),(0,t.jsx)("span",{className:"mt-2 block text-sm text-lytix-navy/80 group-hover:text-lytix-teal",children:"Read more..."})]})]},e.id))}),y<A.length&&(0,t.jsx)("div",{className:"mt-8 text-center",children:(0,t.jsx)("button",{type:"button",onClick:()=>g(e=>Math.min(e+20,A.length)),className:"text-sm font-semibold text-lytix-teal hover:underline uppercase tracking-wider",children:"Load more"})})]})]})]})})]}),(0,t.jsx)("section",{className:"py-12 bg-lytix-light border-t border-lytix-ice",children:(0,t.jsxs)("div",{className:"container mx-auto px-4 lg:px-8 text-center max-w-2xl",children:[(0,t.jsx)("p",{className:"text-lytix-navy/85 text-sm mb-4",children:"For the full archive of regulatory news releases, visit Oslo Børs NewsWeb."}),(0,t.jsxs)("a",{href:"https://newsweb.oslobors.no/search?category=&issuer=7893&fromDate=&toDate=&market=&messageTitle=",target:"_blank",rel:"noopener noreferrer",className:"inline-flex items-center gap-2 text-sm font-bold text-lytix-teal hover:underline",children:["Visit Oslo Børs NewsWeb",(0,t.jsx)(r.ExternalLink,{className:"size-4"})]})]})})]})}e.s(["default",()=>u],279434)}]);